The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Abstract
Chronic low-grade inflammation is a recognized key feature associated with type 2 diabetes mellitus (T2DM) and its complications. In prospective randomized trials, sodium-glucose cotransporter type 2 (SGLT2) inhibitors have demonstrated benefits related to several cardiovascular and renal risk factors, including HbA1c, blood pressure, body weight, renal hyperfiltration, and improvement of cardiorenal outcomes. SGLT2 inhibitors may improve adipose tissue function and induce decreases in serum leptin, TNF-α and IL-6 while increasing adiponectin. While data on high-sensitivity C-reactive protein and other inflammatory markers are relatively scarce in humans, in animals, a number of reports have shown reductions in cytokine and chemokine concentrations in parallel with protective effects against progression of atherosclerotic lesions. Experimental findings also suggest that part of the renoprotective effects of SGLT2 inhibition may be related to anti-inflammatory actions at the kidney level. Underlying mechanisms to explain this anti-inflammatory effect are multiple, but may involve weight loss, and reduction in adipose tissue inflammation, slight increase in ketone bodies and diminution of uric acid levels or attenuation of oxidative stress. However, further studies in diabetes patients with specific assessment of inflammatory markers are still necessary to determine the specific contribution of the anti-inflammatory action of SGLT2 inhibitors to the reduction of cardiovascular and renal complications and mortality observed with this class of antidiabetic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961
Obesity, Inflammation, and Insulin Resistance
Shoelson, S. E., Herrero, L., & Naaz, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.059 · Cited by 1,806
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Ketone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Stehouwer, C. D. A., Gall, M.-A., Twisk, J. W. R., Knudsen, E., Emeis, J. J., & Parving, H.-H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1157 · Cited by 652
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Systemic Inflammation, Adipose Tissue Tumor Necrosis Factor, and Leptin Expression
Bulló, M., García‐Lorda, P., Megias, I., & Salas‐Salvadó, J. (2003) · Obesity Research · doi:10.1038/oby.2003.74 · Cited by 449
Soluble Uric Acid Activates the NLRP3 Inflammasome
Braga, T. T., Forni, M. F., Correa-Costa, M., Ramos, R. N., Barbuto, J. A., Branco, P., Castoldi, A., Hiyane, M. I., Davanso, M. R., Latz, E., et al. (2017) · Scientific Reports · doi:10.1038/srep39884 · Cited by 440
The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages
Rahman, M., Muhammad, S., Khan, M. A., Chen, H., Ridder, D. A., Müller-Fielitz, H., Pokorná, B., Vollbrandt, T., Stölting, I., Nadrowitz, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4944 · Cited by 427
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396
Dror, E., Dalmas, E., Meier, D. T., Wueest, S., Thévenet, J., Thienel, C., Timper, K., Nordmann, T. M., Traub, S., Schulze, F., et al. (2017) · Nature Immunology · doi:10.1038/ni.3659 · Cited by 394
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., Sato, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0658-8 · Cited by 378
Solini, A., Giannini, L., Seghieri, M., Vitolo, E., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0621-8 · Cited by 373
Festa, A., D'agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00331.x · Cited by 369
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Islet inflammation in type 2 diabetes and physiology
Eguchi, K., & Nagai, R. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88877 · Cited by 361
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Zhao, Y., Xu, L., Tian, D., Xia, P., Zheng, H., Wang, L., & Chen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13101 · Cited by 333
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T., Pais, P., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 329
Metabolic regulation of NLRP 3
Hughes, M. M., & O'Neill, L. A. J. (2018) · Immunological Reviews · doi:10.1111/imr.12608 · Cited by 311
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
Wang, X. X., Levi, J., Luo, Y., Myakala, K., Herman-Edelstein, M., Qiu, L., Wang, D., Peng, Y., Grenz, A., Lucia, S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779520 · Cited by 306
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Kashani, F., Roohani, S., Welschof, P., Kopp, M., Gödtel-Armbrust, U., Xia, N., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.009 · Cited by 298
Oelze, M., Kröller-Schön, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinßius, E., Agdauletova, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112394 · Cited by 293
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
Role of NLRP3 Inflammasomes in Atherosclerosis
Karasawa, T., & Takahashi, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17001 · Cited by 276
Role of immune cells in obesity induced low grade inflammation and insulin resistance
Asghar, A., & Sheikh, N. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.03.001 · Cited by 274
Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M., & Hada, T. (2003) · Metabolism · doi:10.1053/meta.2003.50096 · Cited by 270
Diabetic nephropathy – is this an immune disorder?
Tesch, G. H. (2017) · Clinical Science · doi:10.1042/cs20160636 · Cited by 264
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13301 · Cited by 263
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Pollack, R. M., Donath, M. Y., LeRoith, D., & Leibowitz, G. (2016) · Diabetes Care · doi:10.2337/dcs15-3015 · Cited by 262
Garvey, W. T., Van Gaal, L., Leiter, L. A., Vijapurkar, U., List, J., Cuddihy, R., Ren, J., & Davies, M. J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.02.002 · Cited by 261
Shigiyama, F., Kumashiro, N., Miyagi, M., Ikehara, K., Kanda, E., Uchino, H., & Hirose, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0564-0 · Cited by 249
Inflammageing and metaflammation: The yin and yang of type 2 diabetes
Prattichizzo, F., De Nigris, V., Spiga, R., Mancuso, E., La Sala, L., Antonicelli, R., Testa, R., Procopio, A. D., Olivieri, F., & Ceriello, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.10.003 · Cited by 249
Lee, D. M., Battson, M. L., Jarrell, D. K., Hou, S., Ecton, K. E., Weir, T. L., & Gentile, C. L. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0708-x · Cited by 246
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Esser, N., L’homme, L., De Roover, A., Kohnen, L., Scheen, A. J., Moutschen, M., Piette, J., Legrand-Poels, S., & Paquot, N. (2013) · Diabetologia · doi:10.1007/s00125-013-3023-9 · Cited by 239
Self-citationJardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234
Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151511 · Cited by 228
Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Sharma, A., Tate, M., Mathew, G., Vince, J. E., Ritchie, R. H., & de Haan, J. B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00114 · Cited by 215
Yamanashi, T., Iwata, M., Kamiya, N., Tsunetomi, K., Kajitani, N., Wada, N., Iitsuka, T., Yamauchi, T., Miura, A., Pu, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08055-1 · Cited by 214
Díaz-Rodríguez, E., Agra, R. M., Fernández, Á. L., Adrio, B., García-Caballero, T., González-Juanatey, J. R., & Eiras, S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvx186 · Cited by 214
Spiga, R., Marini, M. A., Mancuso, E., Di Fatta, C., Fuoco, A., Perticone, F., Andreozzi, F., Mannino, G. C., & Sesti, G. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309128 · Cited by 209
Al Rifai, M., Silverman, M. G., Nasir, K., Budoff, M. J., Blankstein, R., Szklo, M., Katz, R., Blumenthal, R. S., & Blaha, M. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.011 · Cited by 208
Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 191
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
Bouchi, R., Terashima, M., Sasahara, Y., Asakawa, M., Fukuda, T., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0516-8 · Cited by 175
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 170
Self-citationSGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., & Utsunomiya, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051083 · Cited by 168
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 167
A major role of insulin in promoting obesity-associated adipose tissue inflammation
Pedersen, D. J., Guilherme, A., Danai, L. V., Heyda, L. M., Matevossian, A., Cohen, J. L., Nicoloro, S. M. C., Straubhaar, J., Noh, H. L., Jung, D.-Y., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.003 · Cited by 153
Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.07.002 · Cited by 148
Gaspari, T. A., Spizzo, I., Liu, H., Hu, Y., Simpson, R. W., Widdop, R. E., & Dear, A. E. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117733626 · Cited by 142
Xu, L., & Ota, T. (2017) · Adipocyte · doi:10.1080/21623945.2017.1413516 · Cited by 134
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 133
Fukuda, T., Bouchi, R., Terashima, M., Sasahara, Y., Asakawa, M., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0279-y · Cited by 129
Prattichizzo, F., Nigris, V. D., Micheloni, S., Sala, L. L., & Ceriello, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13488 · Cited by 124
Salim, H. M., Fukuda, D., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00043 · Cited by 123
Relation of Abdominal Fat Depots to Systemic Markers of Inflammation in Type 2 Diabetes
Sam, S., Haffner, S. M., Davidson, M. H., D’Agostino, R. B., Feinstein, S. B., Kondos, G. T., Pérez, A., & Mazzone, T. (2009) · Diabetes Care · doi:10.2337/dc08-1856 · Cited by 121
Ishibashi, Y., Matsui, T., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555791 · Cited by 119
El-Daly, M., Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Kang, S., Fedak, P. W. M., Alston, L. A., Hirota, S. A., Ding, H., Triggle, C. R., et al. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.06.006 · Cited by 117
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
Jaikumkao, K., Pongchaidecha, A., Chueakula, N., Thongnak, L., Wanchai, K., Chatsudthipong, V., Chattipakorn, N., & Lungkaphin, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13441 · Cited by 113
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 108
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 108
Multiple benefits of targeting inflammation in the treatment of type 2 diabetes
Donath, M. Y. (2016) · Diabetologia · doi:10.1007/s00125-016-3873-z · Cited by 101
Nakatsu, Y., Kokubo, H., Batmunkh, B., Yoshizumi, M., Yamamotoya, T., Matsunaga, Y., Ueda, K., Inoue, Y., Inoue, M., Fujishiro, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081704 · Cited by 94
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12834 · Cited by 94
Linking uric acid metabolism to diabetic complications
Kushiyama, A., Tanaka, K., Hara, S., & Kawazu, S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.787 · Cited by 92
Sugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Nishimura, H., Suzuki, T., MIYAMOTO, F., Kajiwara, K., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0701-17 · Cited by 92
Simon, T. G., Trejo, M. E. P., McClelland, R. L., Bradley, R. D., Blaha, M. J., Zeb, I., Corey, K. E., Budoff, M. J., & Chung, R. T. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.01.046 · Cited by 89
Perkins, J. M., Joy, N. G., Tate, D. B., & Davis, S. N. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2015 · Cited by 80
Jobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12881 · Cited by 79
Genç, H., Doğru, T., Kara, M., Tapan, S., Erçin, C. N., Açıkel, C., Karslıoğlu, Y., & Bağcı, S. (2013) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31338-9 · Cited by 72
Okamoto, A., Yokokawa, H., Sanada, H., & Naito, T. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0137-9 · Cited by 67
Polidori, D., Iijima, H., Goda, M., Maruyama, N., Inagaki, N., & Crawford, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13224 · Cited by 66
Chiang, C.-H., Huang, C., Chan, W., Chen, J., & Leu, H. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.09.003 · Cited by 65
Kurinami, N., Sugiyama, S., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouch, K., Jinnouchi, T., & Jinnouchi, H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.017 · Cited by 63
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 62
Möller, K., Ostermann, A. I., Rund, K. M., Thoms, S., Blume, C. A., Stahl, F., Hahn, A., Schebb, N. H., & Schuchardt, J. P. (2015) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.12.001 · Cited by 58
Islet inflammation in type 2 diabetes
Marchetti, P. (2016) · Diabetologia · doi:10.1007/s00125-016-3875-x · Cited by 57
Kumar, D., Shankar, K., Patel, S., Gupta, A., Varshney, S., Gupta, S., Rajan, S., Srivastava, A., Vishwakarma, A. L., & Gaikwad, A. N. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.05.010 · Cited by 55
Yadav, R., Hama, S., Liu, Y., Siahmansur, T. J., Schofield, J. D., Syed, A. A., France, M. W., Pemberton, P. W., Adam, S., Ho, J. H., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01512 · Cited by 54
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.019 · Cited by 53
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 51
Self-citationChen, L., Klein, T., & Leung, P. S. (2012) · Current Molecular Medicine · doi:10.2174/156652412802480970 · Cited by 49
Li, B., Wang, Y., Ye, Z., Yang, H., Cui, X., Wang, Z., & Liu, L. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29831 · Cited by 46
Matsumura, M., Nakatani, Y., Tanka, S., Aoki, C., Sagara, M., Yanagi, K., Suzuki, K., & Aso, Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0274-3 · Cited by 41
Pereira, C. A., Carneiro, F. S., Matsumoto, T., & Tostes, R. C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13054 · Cited by 40
Relation Between Epicardial Fat and Subclinical Atherosclerosis in Asymptomatic Individuals
Abazid, R. M., Smettei, O. A., Kattea, M., Sayed, S., Saqqah, H., Widyan, A. M., & Opolski, M. P. (2017) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000296 · Cited by 39
Tanaka, A., Shimabukuro, M., Okada, Y., Taguchi, I., Yamaoka‐Tojo, M., Tomiyama, H., Teragawa, H., Sugiyama, S., Yoshida, H., Sato, Y., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0532-8 · Cited by 37
Takeda, A., Irahara, A., Nakano, A., Takata, E., Koketsu, Y., Kimata, K., Senda, E., Yamada, H., Ichikawa, K., Fujimori, T., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8754-16 · Cited by 37
Hattori, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12781 · Cited by 37
Inflammatory stress in islet β-cells: therapeutic implications for type 2 diabetes?
Lytrivi, M., Igoillo‐Esteve, M., & Cnop, M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.002 · Cited by 30
Ekholm, E., Hansen, L., JOHNSSON, E. K., Iqbal, N., Carlsson, B., Chen, H., & Hirshberg, B. (2016) · Endocrine Practice · doi:10.4158/ep161323.or · Cited by 27
Ishibashi, Y., Matsui, T., & Yamagishi, S. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116657304 · Cited by 24
Berk, K. A., Oudshoorn, T. P., Verhoeven, A. J. M., Mulder, M. T., Roks, A. J. M., Dik, W. A., Timman, R., & Sijbrands, E. J. G. (2016) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2016.06.011 · Cited by 18
Djindjić, B., Kostić, T. L., Radovanovic, Z., Djindjić, N., Lazović, M., Živić, M., Perišić, Z., & Krstić, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.089 · Cited by 16
Bi, Y., Min, M., Shen, W., Deng, P., Du, Q., Dong, M., & Liu, Y. (2015) · PubMed · Cited by 8
Cited by
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis
Chung, K. W., Dhillon, P., Huang, S., Sheng, X., Shrestha, R., Qiu, C., Kaufman, B. A., Park, J., Pei, L., Baur, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.003 · Cited by 651
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Metadata
- Authors
- Bonnet, F., & Scheen, A. J.
- Venue
- Diabetes & Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 44
- Issue
- 6
- Pages
- 457-464
- ISSN
- 1262-3636 (ISSN-L)
- OpenAlex
- W2892498615
- Cited by
- 308
- References
- 125
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.